Nanologica

Nanologica AB is a Swedish life science tools company, founded in 2004, that emerged from materials science research focused on new porous materials. The company has since cultivated deep expertise in nanotechnology and chromatography, establishing itself as a key player in the production of nanoporous silica particles. Publicly traded on the Nasdaq Stockholm Main Market under the ticker NICA, Nanologica serves a global market, with a significant presence in China, India, and the United States.

The company's business model centers on the development, manufacturing, and sale of advanced consumables to pharmaceutical manufacturers. Revenue is generated through direct sales, licensing agreements, and fee-for-service contracts for technology access and feasibility trials. A key milestone was a 2019 agreement with Chinese distributor Yunbo Technology for the supply of preparative silica worth approximately 128 million SEK, running from 2021 to 2026. For large-scale production, Nanologica partners with contract manufacturers in the UK and Ireland, ensuring multi-ton scale capacity while maintaining control over the entire proprietary manufacturing process.

Nanologica’s core product is NLAB Saga®, a perfectly spherical, porous silica media designed for preparative chromatography. This product is crucial for the large-scale purification of peptide-based drugs, such as insulin and GLP-1 analogues used in treating diabetes and obesity. The key benefits of NLAB Saga® stem from its proprietary manufacturing process, which allows for precise control over particle size, shape, and porosity. This results in exceptional mechanical and chemical stability, a longer product lifetime, and more effective purification. For pharmaceutical clients, this translates into higher productivity and reduced manufacturing costs, with the ultimate mission of making vital medicines more accessible to patients globally. The company has also demonstrated an ability to nurture new ventures, having spun off concepts like Exeger (indoor solar cells) in 2011 and Sigrid Therapeutics (obesity treatment) in 2014.

Andreas Bhagwani has been the CEO since 2011 and is a significant shareholder. His background includes an EMBA from the Stockholm School of Economics and over a decade as a management consultant specializing in sales and leadership. Bhagwani is a serial entrepreneur, having co-founded several companies, including Sigrid Therapeutics AB and Atrogi AB, both related to metabolic diseases, which directly aligns with Nanologica's focus on purification for diabetes and obesity drugs. Keywords: Nanoporous silica, preparative chromatography, peptide purification, GLP-1 analogues, insulin manufacturing, life science tools, pharmaceutical consumables, drug purification media, NLAB Saga, materials science, Swedish biotech, Nasdaq Stockholm NICA, Andreas Bhagwani, chromatography consumables, diabetes treatment manufacturing, obesity drug purification, pharmaceutical production cost reduction, silica particles, high-performance liquid chromatography, API purification